Rosuvastatin for Preventing Complications in Renal Ablation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 112 participants.

Also called NCT01899027

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 112 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01899027
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01899027. Randomized; single masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2016-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rosuvastatin for Preventing Complications in Renal Ablation
Acronym
ARTEMISIA
Condition
Arterial Hypertension
Intervention (Drug)
Rosuvastatin
Intervention (Drug)
Placebo
Lead sponsor
University of Roma La Sapienza (class: other)

Record details

Record id
cardio:ct-nct01899027
Content hash
4de5447f758c22c61de3d2386d0970f5e759104967f20eaa2209243337b76ac6